Connor, Clark & Lunn Investment Management (CC&L)
BHVN

Connor, Clark & Lunn Investment Management (CC&L)’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,207
Closed -$966K – 1215
2020
Q2 		$966K Buy
+13,207
New +$703K 0.01% 624

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BHVN Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2020, closing a stake of 13,207 shares — an estimated $966K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BHVN in Q2 2020 and held it in 1 quarter. The position peaked at $966K in Q2 2020. 215 funds tracked by Wall St. Rank hold BHVN as of Q3 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 13,207 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2020, an estimated $966K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Biohaven Pharmaceutical Holding Company Ltd. position peaked at $966K in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.